|
| Status |
Public on May 16, 2023 |
| Title |
CLARITY study: Expression data from RRMS patients treated with Oral Cladribine versus Placebo at week 96 |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
The CLARITY trial (NCT00213135) was designed as a double-blind, placebo-controlled study to allow the best comparison of absolute efficacy and safety of oral cladribine in RRMS subjects. 1326 patients with relapsing MS were randomized (1:1:1) to receive cladribine tablets 3.5 mg/kg or 5.25 mg/kg bodyweight or placebo. Gene expression data in whole blood samples at 96 weeks were prepared according to standard Affymetrix protocols
Gene expression data in whole blood samples at 96 weeks were available from patients randomized to placebo (n=57), cladribine tablets 3.5 mg/kg (n=62), and cladribine tablets 5.25 mg/kg (n=70).
|
| |
|
| Overall design |
Transcriptome of the whole blood from RRMS patients either treated with high (5.25 mg/kg) or low dose (3.5 mg/kg) of cladribine or from placebo arm at 96 weeks after start day.
|
| Web link |
https://pubmed.ncbi.nlm.nih.gov/37202447/
|
| |
|
| Contributor(s) |
Kalatskaya I, Boschert U |
| Citation(s) |
37202447 |
| |
| Submission date |
Oct 12, 2021 |
| Last update date |
Aug 08, 2023 |
| Contact name |
Irina Kalatskaya |
| E-mail(s) |
irina.kalatskaya@emdserono.com
|
| Organization name |
EMD Serono Research and Development Institute
|
| Department |
Clinical Measurement Sciences
|
| Street address |
45 Middlesex Turnpike
|
| City |
Billerica |
| State/province |
MA |
| ZIP/Postal code |
01821 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (189)
|
|
| Relations |
| BioProject |
PRJNA770732 |
Less...
More...